Methods of treating cancers with CT45 targeted therapies

Patent metadata

Field	Value
Publication number	US-11261223-B2
Application number	US-201716300267-A
Country	US
Kind code	B2
Filing date	May 11, 2017
Priority date	May 11, 2016
Publication date	Mar 1, 2022
Grant date	Mar 1, 2022

Abstract

The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.

First claim

The invention claimed is:

1. A method for treating ovarian cancer in a patient comprising administering isolated T cells comprising a T cell receptor (TCR) that is stimulated upon contact with a CT45 polypeptide to the patient, wherein the CT45 polypeptide consists of one of SEQ ID NOS:1-6 or 29-33.

2. The method of claim 1 , wherein the patient has been determined to have a CT45-expressing ovarian cancer.

3. The method of claim 1 , wherein the ovarian cancer is high-grade serous ovarian cancer (HGSOC).

4. The method of claim 1 , wherein the T cells are autologous.

5. The method of claim 1 , wherein the method comprises administering T cells to the patient and wherein the T cells are contacted with one or more of IL-2, anti-CD3, and allo-reactive feeder cells prior to administration to the patient.

6. The method of claim 5 , wherein the method further comprises lymphodepletion of the patient prior to administration of the T cells.

7. The method of claim 5 , wherein the method further comprises administration of IL-2.

8. The method of claim 1 , wherein the method comprises administering T cells to the patient and wherein the T cells have been contacted with a maturation agent.

9. The method of claim 8 , wherein the maturation agent is one or more of GM-CSF, IL-1β, TNF-α, and PGE2.

10. The method of claim 1 , wherein the method further comprises administration of an additional therapeutic agent and wherein the additional therapeutic is selected from a chemotherapeutic agent, a checkpoint inhibitor, a MUC-1 inhibitor, a CD40 activator, an IDO inhibitor, and an OX86 agonists.

11. The method of claim 10 , wherein the additional therapeutic is a chemotherapeutic agent and wherein the chemotherapeutic agent comprises a DNA damaging agent.

12. The method of claim 11 , wherein the DNA damaging agent is a platinum-containing compound.

13. The method of claim 12 , wherein the compound is cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, or satraplatin.

14. The method of claim 1 , wherein the method further comprises administration of an ionizing radiation therapy.

15. The method of claim 1 , wherein the method further comprises administration of a DNA methyltransferase inhibitor prior to administration of the T cells.

16. A method for treating ovarian cancer in a patient comprising administering autologous T cells comprising a T cell receptor (TCR) that is stimulated upon contact with a CT45 polypeptide to the patient, wherein the CT45 polypeptide consists of SEQ ID NO:1.

Assignees

• Univ Chicago
• Max Planck Gesellschaft

Inventors

• Lengyel Ernst
• Mann Matthias
• Curtis Marion
• Coscia Fabian

Classifications

• G01N33/57545

  of the ovaries · CPC title

• A61K2039/5158

  Antigen-pulsed cells, e.g. T-cells · CPC title

• A61K2039/5154

  Antigen presenting cells [APCs], e.g. dendritic cells or macrophages · CPC title

• A61K35/17

  Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) · CPC title

• A61K40/4267

  Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE · CPC title